Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [BRAF mutation detection in metastatic melanoma].

Literature DB >> 22692278

[BRAF mutation detection in metastatic melanoma].

M Dietel¹, A Enk, A Lehmann, J Bauer, C Garbe, U Kellner, T Kirchner, A Jung, H Kreipe, S Merkelbach-Bruse, R Büttner, J Rüschoff, W Schlake, P Schirmacher, R Penzel, R Stadler.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2012 PMID： 22692278 DOI： 10.1007/s00292-012-1609-5

Source DB: PubMed Journal: Pathologe ISSN： 0172-8113 Impact factor: 1.011

× No keyword cloud information.

11 in total

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245

2. [Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer].

Authors: M Dietel; A Tannapfel; G Baretton; H Kreipe; M Kloor; H Gabbert; T Kirchner
Journal: Chirurg Date: 2008-06 Impact factor: 0.955

3. Distinct sets of genetic alterations in melanoma.

Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245

Review 4. Raf kinases in cancer-roles and therapeutic opportunities.

Authors: G Maurer; B Tarkowski; M Baccarini
Journal: Oncogene Date: 2011-05-16 Impact factor: 9.867

5. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Authors: Georgina V Long; Alexander M Menzies; Adnan M Nagrial; Lauren E Haydu; Anne L Hamilton; Graham J Mann; T Michael Hughes; John F Thompson; Richard A Scolyer; Richard F Kefford
Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544

Review 6. Targeting metastatic melanoma.

Authors: Keith T Flaherty
Journal: Annu Rev Med Date: 2011-10-27 Impact factor: 13.739

7. Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245

Review 8. Towards new therapeutic approaches for malignant melanoma.

Authors: Ivan Pacheco; Cristina Buzea; Victor Tron
Journal: Expert Rev Mol Med Date: 2011-11-01 Impact factor: 5.600

Review 9. BRAF inhibitors and melanoma.

Authors: Keith T Flaherty
Journal: Cancer J Date: 2011 Nov-Dec Impact factor: 3.360

10. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245

3 in total